

October 17, 2022  
Fuji Pharma Co., Ltd.

## **Submission of a Marketing Approval Application for the 1st Biosimilar Product Developed under Alvotech Partnership**

Fuji Pharma Co., Ltd. ("Fuji") announced today that Fuji has submitted an application for marketing approval of the first biosimilar product for the Japanese market developed under the exclusive development and commercialization partnership with Alvotech (Head Office: Iceland) to the Ministry of Health, Labor and Welfare (MHLW).

On November 16, 2018, Fuji and Alvotech announced "[ALVOTECH AND FUJI PHARMA ENTER INTO EXCLUSIVE PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF BIOSIMILARS IN JAPAN](#)", after Fuji and Alvotech agreed to form an exclusive partnership for development and commercialization of biosimilars in Japan. Since 2018, Alvotech and Fuji have expanded this exclusive partnership to include six biosimilar candidates. Submission of the first biosimilar marketing approval application in this partnership will further strengthen Fuji's domestic biosimilar line-up. .

In our Mid-Term Business Plan (FY9/2020-9/2024), we have set the goal of becoming the market leader in the biosimilar segment in Japan by the FY9/2029. Fuji will continue to expand biosimilar lineups to deliver high quality biosimilar products to Japanese market and contribute to patients, medical field and medical economics.

### **For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsks@fujipharma.jp](mailto:fsks@fujipharma.jp)